


In patients with or without brain metastases,

MEET ALK+ advanced NSCLC
HEAD ON
WITH LORVIQUA¹

Pfizer is pleased to announce that LORVIQUA[®] (lorlatinib) has been granted approval by the Health Sciences Authority of Singapore (HSA) for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).¹

The National Comprehensive Cancer Network (NCCN) guidelines for NSCLC recommends LORVIQUA[®] (lorlatinib) as a category 1 treatment option in the first line setting.² This endorsement is an addition to the existing recommendation for LORVIQUA[®] (lorlatinib) as subsequent therapy for patients previously treated alectinib or ceritinib, or with crizotinib and one other ALK tyrosine kinase inhibitor (TKI).²

To support you in providing care for your patients seeking treatment with LORVIQUA[®] (lorlatinib), we have developed a Therapy Management Guide, which you can download by scanning the QR code or clicking on the button below.



LORVIQUA Therapy Management Guide


References:

1. Pfizer. LORVIQUA[®] (lorlatinib) Prescribing Information. Available from: <http://labeling.pfizer.com/ShowLabeling.aspx?id=12540>.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Non-Small Cell Lung Cancer V.3.2022 © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 27th 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Full Prescribing Information

To access the LORVIQUA[®] (lorlatinib) Prescribing Information, please scan the QR code below or visit: <https://labeling.pfizer.com/ShowLabeling.aspx?id=12540>.

LORVIQUA[®] (lorlatinib) is available as 25mg and 100mg tablets.



For Healthcare Professionals only

Full prescribing information is available upon request

To report any Adverse Events related to Pfizer pharmaceutical products, please contact us via the following: SGP.AEReporting@pfizer.com
If you have any medical enquiries about Pfizer pharmaceutical products, please contact our medical information services: medicalinformationsingapore@pfizer.com



Pfizer Private Limited
80 Pasir Panjang Road, #16-81/82,
Mapletree Business City, Singapore 117372
Copyright © 2022 Pfizer